welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
UT researcher, with CureDuchenne support, launches company to treat DMD using CRISPR/Cas9 technology
Eric Olson, a molecular biologist, has spent more than half his life in the lab. Now, the 62-year-old University of Texas researcher and distinguished professor is a businessman as well.
Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.
The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD).
rareRelated
-
Researchers Overcome Hurdle in CRISPR Gene Editing for Muscular DystrophyThe gene editing technique known as CRIS...
-
Crispr Halted Muscular Dystrophy In Dogs. Someday, It Might Cure Humans.Today, our partner Dr. Eric Olson and hi...
-
New CRISPR technique skips over portions of genes that can cause diseaseIn a new study in cells, researchers hav...
-
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
-
New CRISPR Method Takes on Duchenne Muscular DystrophyThe advance of CRISPR gene editing techn...
-
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exon...CureDuchenne, a nonprofit global leader ...
-
Development of a CRISPR-based gene therapy approach targeting the large exon 45-exon 55 mutation hotspot in DMD geneGene replacement and exon skipping thera...